

# Katie E Barber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6420502/publications.pdf>

Version: 2024-02-01

55  
papers

1,240  
citations

394421

19  
h-index

377865

34  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variation Among Infectious Diseases Pharmacists for the Treatment of <i>Staphylococcus aureus</i> Bacteremia. <i>Journal of Pharmacy Practice</i> , 2023, 36, 295-302.	1.0	3
2	Intravenous versus Oral Step-Down for the Treatment of <i>Staphylococcus aureus</i> Bacteremia in a Pediatric Population. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 16.	1.6	3
3	Frequency of and risk factors for carbapenem-resistant Enterobacteriaceae. <i>Journal of Medical Microbiology</i> , 2021, 70, .	1.8	3
4	Ceftriaxone as an Alternative Therapy for the Treatment of Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia after Initial Clearance of Bloodstream Infection. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-6.	0.5	4
5	Effect of Obesity on Clinical Failure of Patients Treated With $\beta$ -Lactams. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab212.	0.9	7
6	Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant <i>Enterococcus faecium</i> and <i>faecalis</i> . <i>Antibiotics</i> , 2021, 10, 897.	3.7	8
7	A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2020. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab422.	0.9	3
8	Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 175.	1.6	6
9	Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab554.	0.9	18
10	Impact of Obesity on Ceftriaxone Efficacy. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 27.	2.5	6
11	Impact of Obesity in Patients with <i>Candida</i> Bloodstream Infections: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 175-183.	4.0	11
12	Impact of Obesity on Acyclovir-Induced Nephrotoxicity. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz121.	0.9	10
13	Effect of fish oil supplement administration method on tolerability and adherence: a randomized pilot clinical trial. <i>Pilot and Feasibility Studies</i> , 2019, 5, 3.	1.2	4
14	The Current Landscape of Veterinary Compounding in the Pharmacy Setting. <i>International Journal of Pharmaceutical Compounding</i> , 2019, 23, 422-427.	0.0	2
15	Impact of an antifungal stewardship intervention on optimization of candidemia management. <i>Therapeutic Advances in Infectious Disease</i> , 2018, 5, 3-10.	1.8	12
16	Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections. <i>Nurse Practitioner</i> , 2018, 43, 31-37.	0.3	4
17	Omadacycline Enters the Ring: A New Antimicrobial Contender. <i>Pharmacotherapy</i> , 2018, 38, 1194-1204.	2.6	20
18	Impact of an infectious diseases advanced pharmacy practice experience on student knowledge. <i>Currents in Pharmacy Teaching and Learning</i> , 2018, 10, 1022-1025.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2405-2410.	3.0	12
20	Risk Factors for Failure in Complicated Intraabdominal Infections. <i>Southern Medical Journal</i> , 2018, 111, 125-132.	0.7	3
21	Ceftaroline for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 201-208.	1.0	17
22	Managing acute bacterial skin and skin structure infections. <i>Nurse Practitioner</i> , 2017, 42, 1-6.	0.3	0
23	Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 11, 111-113.	2.2	6
24	Timeâ€Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid <i>Pseudomonas aeruginosa</i> Strains from Cystic Fibrosis Patients. <i>Infectious Diseases and Therapy</i> , 2017, 6, 507-513.	4.0	6
25	Mechanisms of fosfomycin resistance in carbapenem-resistant <i>Enterobacter</i> sp .. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 690-692.	2.5	6
26	Successful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of Linezolid. <i>Case Reports in Infectious Diseases</i> , 2017, 2017, 1-3.	0.5	6
27	Dalbavancin use for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> pneumonia. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017, 8, 77.	0.4	16
28	Ceftazidime/Avibactam: Who Says You Canâ€™t Teach an Old Drug New Tricks?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 448.	2.1	11
29	Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. <i>International Journal of Hepatology</i> , 2016, 2016, 1-8.	1.1	29
30	Pronounced heterogeneity observed in high-level daptomycin-resistant viridans group streptococci. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 159-166.	2.2	3
31	Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible <i>Staphylococcus aureus</i> in an In Vitro , Hollow-Fiber Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3970-3975.	3.2	16
32	Implementation of Twitter and Google Voice to simulate a pharmacy residentâ€™s day on-call for third-year pharmacy students. <i>Currents in Pharmacy Teaching and Learning</i> , 2016, 8, 804-810.	1.0	0
33	Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , 2016, 5, 367-377.	4.0	7
34	Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application. <i>Drugs and Aging</i> , 2016, 33, 845-854.	2.7	20
35	Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 631-634.	0.6	14
36	Evaluation of tedizolid against <i>Staphylococcus aureus</i> and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 152-155.	3.0	64

#	ARTICLE	IF	CITATIONS
37	Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent <i>Candida</i> spp.. <i>Journal of Medical Microbiology</i> , 2016, 65, 1445-1451.	1.8	10
38	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1272-1273.	3.0	1
39	Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant <i>Staphylococcus aureus</i> with Reduced Susceptibility to Daptomycin and Vancomycin in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4497-4503.	3.2	41
40	Therapeutic options for vancomycin-resistant enterococcal bacteremia. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 363-377.	4.4	30
41	Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 489-493.	3.0	35
42	$\beta$ -Lactam combinations with daptomycin provide synergy against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1738-1743.	3.0	99
43	Telavancin Demonstrates Activity against Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5529-5534.	3.2	22
44	$\beta$ -Lactams Enhance Daptomycin Activity against Vancomycin-Resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> in <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2842-2848.	3.2	40
45	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 311-313.	3.0	39
46	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 505-509.	3.0	36
47	A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2989-2992.	3.2	36
48	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2148-2154.	3.0	53
49	Observation of "Seesaw Effect" with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150 Unique MRSA Strains. <i>Infectious Diseases and Therapy</i> , 2014, 3, 35-43.	4.0	63
50	Potent synergy of ceftobiprole plus daptomycin against multiple strains of <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3006-3010.	3.0	50
51	High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It. <i>Current Infectious Disease Reports</i> , 2014, 16, 429.	3.0	23
52	Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant <i>Staphylococcus aureus</i> in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3177-3181.	3.2	44
53	Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2541-2546.	3.2	97
54	Current and prospective treatments for multidrug-resistant gram-positive infections. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1919-1932.	1.8	40

#	ARTICLE	IF	CITATIONS
55	Carbapenem-resistant <i>Acinetobacter baumannii</i> : epidemiology, surveillance and management. Expert Review of Anti-Infective Therapy, 2013, 11, 383-393.	4.4	118